Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

King Faisal Specialist Hospital & Research Center8 enrolled

Overview

Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse. (CALYPSO)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Epithelial Ovarian Cancer

Interventions

pegylated liposomal Doxorubicin (CAELYX) & CarboplatinDRUG

Chemotherapy

Paclitaxel & CarboplatinDRUG

Chemotherapy

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with epithelial Ovarian cancer in late relapse

Outcomes

Primary Outcomes

overall survival

Time frame: overall

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.